Table of Contents Author Guidelines Submit a Manuscript
Parkinson’s Disease
Volume 2014, Article ID 158353, 7 pages
http://dx.doi.org/10.1155/2014/158353
Clinical Study

Are Branded and Generic Extended-Release Ropinirole Formulations Equally Efficacious? A Rater-Blinded, Switch-Over, Multicenter Study

1Department of Neurology, University of Pécs, Rét Utca 2, Pécs 7623, Hungary
2Department of Neurology, Kaposi Mór County Hospital, Tallián Gyula Utca 20-32, Kaposvár 7400, Hungary
3MTA-PTE Clinical Neuroscience MR Research Group, Rét Utca 2, Pécs 7623, Hungary
4Department of Neurology, Health Center of City of Pécs, Dr. Veress Endre Utca 2, Pécs 7633, Hungary
5Institute of Behavioral Sciences, University of Pécs, Szigeti Utca 12, Pécs 7624, Hungary
6Department of Neurosurgery, University of Pécs, Rét Utca 2, Pécs 7623, Hungary

Received 16 May 2014; Revised 29 July 2014; Accepted 29 July 2014; Published 26 August 2014

Academic Editor: Jan O. Aasly

Copyright © 2014 Edit Bosnyák et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. H. Oertel, A. Berardelli, B. R. Bloem et al., “Late (complicated) Parkinson’s disease,” in European Handbook of Neurological Management, N. Gilhus, P. J. Barnes, and M. Brainin, Eds., Blackwell Publishing, Berlin, Germany, 2011. View at Google Scholar
  2. Z. Aschermann, N. Kovács, and S. Komoly, “Continuous dopaminergic stimulation in Parkinson disease: possibilities in 2013,” Ideggyogyaszati Szemle, vol. 66, no. 5-6, pp. 209–210, 2013. View at Google Scholar · View at Scopus
  3. K. Hensler, C. Uhlmann, T. Porschen, R. Benecke, and J. Rösche, “Generic substitution of antiepileptic drugs—a survey of patients' perspectives in Germany and other German-speaking countries,” Epilepsy & Behavior, vol. 27, no. 1, pp. 135–139, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. A. van der Meersch, A. Dechartres, and P. Ravaud, “Quality of reporting of bioequivalence trials comparing generic to brand name drugs: a methodological systematic review,” PLoS ONE, vol. 6, no. 8, Article ID e23611, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. A. S. Raw, R. Lionberger, and L. X. Yu, “Pharmaceutical equivalence by design for generic drugs: modified-release products,” Pharmaceutical Research, vol. 28, no. 7, pp. 1445–1453, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. US Food and Drug Administration, Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products—General Considerations (Revision 1), 2010, http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070124.pdf.
  7. P. Rajna, “The use of generic drugs in the medical therapy of epilepsy,” Lege Artis Medicinae, vol. 15, no. 7, pp. 537–548, 2005. View at Google Scholar · View at Scopus
  8. E. C. Lauterbach, A. Freeman, and R. L. Vogel, “Correlates of generalized anxiety and panic attacks in dystonia and Parkinson disease,” Cognitive and Behavioral Neurology, vol. 16, no. 4, pp. 225–233, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. E. C. Wolters, “Non-motor extranigral signs and symptoms in Parkinson's disease,” Parkinsonism & Related Disorders, vol. 15, supplement 3, pp. S6–S12, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. U. Adamiak, M. Kaldonska, G. Klodowska-Duda et al., “Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced parkinson disease,” Clinical Neuropharmacology, vol. 33, no. 3, pp. 135–141, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. “Committee for medicinal products for human use,” Guideline on the Investigation of Bioequivalence, CPMP/EWP/QWP/1401/98 Rev. 1/Corr, 2010, http://www.ema.europa.eu/ema/pages/includes/document/open_document.jsp?webContentId=WC500070039.
  12. A. Marzo and E. Fontana, “Critical considerations into the new EMA guideline on bioequivalence,” Arzneimittel-Forschung, vol. 61, no. 4, pp. 207–220, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. C. L. Go, R. L. Rosales, P. Schmidt, K. E. Lyons, R. Pahwa, and M. S. Okun, “Generic versus branded pharmacotherapy in Parkinson's disease: does it matter? A review,” Parkinsonism and Related Disorders, vol. 17, no. 5, pp. 308–312, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. EMA/CHMP/QWP/428693/2013 Committee for Medicinal Products for Human Use (CHMP) Guideline on quality of oral modified release products, http://www.ema.europa.eu/ema/pages/includes/document/open_document.jsp?webContentId=WC500170465.
  15. R. Pahwa, J. Marjama, D. McGuire et al., “Pharmacokinetic comparison of sinemet and atamet (generic carbidopa/levodopa): a single-dose study,” Movement Disorders, vol. 11, no. 4, pp. 427–430, 1996. View at Publisher · View at Google Scholar · View at Scopus
  16. U. E. Gasser, A. Fischer, J. P. Timmermans, and I. Arnet, “Pharmaceutical quality of seven generic Levodopa/Benserazide products compared with original Madopar/Prolopa,” BMC Pharmacology and Toxicology, vol. 14, article 24, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. I. Litvan, K. P. Bhatia, D. J. Burn et al., “SIC task force appraisal of clinical diagnostic criteria for parkinsonian disorders,” Movement Disorders, vol. 18, no. 5, pp. 467–486, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. B. Kaszás, N. Kovács, I. Balás et al., “Sensitivity and specificity of Addenbrooke's Cognitive Examination, Mattis Dementia Rating Scale, Frontal Assessment Battery and Mini Mental State Examination for diagnosing dementia in Parkinson's disease,” Parkinsonism and Related Disorders, vol. 18, no. 5, pp. 553–556, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. G. Fehér, I. Balás, S. Komoly et al., “Analysis of antiparkinsonian drug reduction after bilateral subthalamic deep brain stimulation,” Ideggyogyaszati Szemle, vol. 63, no. 9-10, pp. 314–319, 2010. View at Google Scholar · View at Scopus
  20. G. Deli, I. Balás, S. Komoly et al., “Treatment of dystonia by deep brain stimulation: a summary of 40 cases,” Ideggyogyaszati Szemle, vol. 65, no. 7-8, pp. 249–260, 2012. View at Google Scholar · View at Scopus
  21. R. A. Hauser, F. Deckers, and P. Lehert, “Parkinson's disease home diary: further validation amd implications for clinical trials,” Movement Disorders, vol. 19, no. 12, pp. 1409–1413, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. R. A. Hauser, J. Friedlander, T. A. Zesiewicz et al., “A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia,” Clinical Neuropharmacology, vol. 23, no. 2, pp. 75–81, 2000. View at Publisher · View at Google Scholar · View at Scopus
  23. R. A. Hauser, H. Russ, D. Haeger, M. Bruguiere-Fontenille, T. Müller, and G. K. Wenning, “Patient evaluation of a home diary to assess duration and severity of dyskinesia in parkinson disease,” Clinical Neuropharmacology, vol. 29, no. 6, pp. 322–330, 2006. View at Publisher · View at Google Scholar · View at Scopus